Akseli Hemminki is Founder & CEO and Chairman of the Board of TILT Biotherapeutics. Following an award-winning PhD in cancer genetics, Dr Hemminki completed his MD and then moved to the US to learn about gene therapy in 2000. He fell in love with oncolytic viruses and helped set up three clinical trials at the University of Alabama at Birmingham. Subsequent to returning to Finland he specialized in oncology and radiotherapy and set up his research group, the Cancer Gene Therapy Group, at the University of Helsinki. He has won numerous awards, including the Best PhD thesis in the Faculty, the Sigrid Juselius Award, the Duodecim Young Researcher award and the EACR Young European Cancer Researcher Award. He has been involved in a dozen clinical trials, of which most difficult to set up was the first oncolytic virus trial performed in Northern Europe. Hemminki has published more than 240 peer-reviewed manuscripts on cancer research and oncolytic viruses, many of them in the best journals of the field.